VeraDermics Inc. is a dermatology pharmaceutical start-up, makers of WartPatch
Investors 1
Funding Rounds 1
Date | Series | Amount | Investors |
14.12.2024 | Series B | $75M | - |
Mentions in press and media 6
Date | Title | Description |
14.12.2024 | Veradermics Secures $75 Million to Tackle Hair Loss Epidemic | In a world where appearances often dictate confidence, hair loss can feel like a thief in the night. It creeps in silently, leaving millions grappling with its emotional toll. Enter Veradermics, a New Haven-based biopharmaceutical company, ... |
14.12.2024 | Veradermics: $75 Million (Series B) Raised To Develop Therapeutics For Common Dermatologic Conditions | Veradermics – a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class therapeutics for common dermatologic conditions – announced the closing of a $75 million Series B financing. The fina... |
11.12.2024 | Veradermics Raises $75M in Series B Financing | Veradermics, a New Haven, CT-based clinical-stage aesthetics and dermatology-focused biopharmaceutical company, raised $75M in Series B funding.
The round was led by Suvretta Capital Management and included new investors Longitude Capital, ... |
24.03.2023 | Veradermics Doses First Patient in Phase 2 Clinical Trial for VDMN for the Treatment of Common Warts | WEST HARTFORD, Conn. (PRWEB) March 24, 2023
Veradermics Inc., a clinical-stage medical dermatology company with a pipeline of first-in-class product candidates targeting highly prevalent skin conditions, today announced that it has commence... |
23.08.2022 | VeraDermics Inc. Secures Licensing of First-in-Class Antiviral Targeting the Treatment of Molluscum Contagiosum and other Poxviruses | WEST HARTFORD, Conn. (PRWEB) August 23, 2022
VeraDermics Incorporated, developer of drugs for dermatology, today announced that it has entered into a definitive license agreement with the University of Pennsylvania (Penn) for patent rights ... |
- | VeraDermics | “Veradermics, Inc. is a medical dermatology company advancing first-in-class therapeutics that address real-world patient needs in under-innovated dermatology markets.” |
Reviews 0